Treatment of lung large cell neuroendocrine carcinoma

Giuseppe Lo Russo, Sara Pusceddu, Claudia Proto, Marianna Macerelli, Diego Signorelli, Milena Vitali, Monica Ganzinelli, Rosaria Gallucci, Nicoletta Zilembo, Marco Platania, Roberto Buzzoni, Filippo de Braud, Marina Chiara Garassino

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Lung large cell neuroendocrine carcinoma (L-LCNEC) is a rare, aggressive, and difficult-to-treat tumor. It is classified as a neuroendocrine subtype of large cell lung carcinoma (LCLC) belonging to the non-small cell lung cancer (NSCLC) group, but it is also included in the neuroendocrine tumor (NET) group. Most of the available data related to its treatment derive from retrospective analyses or small case series. For patients with L-LCNEC, prognosis is generally very poor. In early stages (I–II–III), surgery is recommended but does not seem to be sufficient. Platinum-based adjuvant chemotherapy may be useful while the role of neoadjuvant chemotherapy is still not well defined. In patients with advanced L-LCNEC, the chemotherapy regimens used in SCLC still remain the standard of treatment, but results are not satisfactory. Due to their peculiar clinical and biological features and the lack of literature data, there is an emerging need for a consensus on the best treatment strategy for L-LCNEC and for the identification of new therapeutic options. In this review, we will discuss the key aspects of L-LCNEC management with the aim to clarify the most controversial issues.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalTumor Biology
DOIs
Publication statusAccepted/In press - Mar 4 2016

Fingerprint

Neuroendocrine Carcinoma
Large Cell Carcinoma
Lung
Therapeutics
Drug Therapy
Neuroendocrine Tumors
Adjuvant Chemotherapy
Platinum
Non-Small Cell Lung Carcinoma
Neoplasms

Keywords

  • Chemotherapy
  • Large cell neuroendocrine carcinoma
  • Lung neuroendocrine tumor
  • Treatment options

ASJC Scopus subject areas

  • Cancer Research

Cite this

Lo Russo, G., Pusceddu, S., Proto, C., Macerelli, M., Signorelli, D., Vitali, M., ... Garassino, M. C. (Accepted/In press). Treatment of lung large cell neuroendocrine carcinoma. Tumor Biology, 1-11. https://doi.org/10.1007/s13277-016-5003-4

Treatment of lung large cell neuroendocrine carcinoma. / Lo Russo, Giuseppe; Pusceddu, Sara; Proto, Claudia; Macerelli, Marianna; Signorelli, Diego; Vitali, Milena; Ganzinelli, Monica; Gallucci, Rosaria; Zilembo, Nicoletta; Platania, Marco; Buzzoni, Roberto; de Braud, Filippo; Garassino, Marina Chiara.

In: Tumor Biology, 04.03.2016, p. 1-11.

Research output: Contribution to journalArticle

Lo Russo G, Pusceddu S, Proto C, Macerelli M, Signorelli D, Vitali M et al. Treatment of lung large cell neuroendocrine carcinoma. Tumor Biology. 2016 Mar 4;1-11. https://doi.org/10.1007/s13277-016-5003-4
Lo Russo, Giuseppe ; Pusceddu, Sara ; Proto, Claudia ; Macerelli, Marianna ; Signorelli, Diego ; Vitali, Milena ; Ganzinelli, Monica ; Gallucci, Rosaria ; Zilembo, Nicoletta ; Platania, Marco ; Buzzoni, Roberto ; de Braud, Filippo ; Garassino, Marina Chiara. / Treatment of lung large cell neuroendocrine carcinoma. In: Tumor Biology. 2016 ; pp. 1-11.
@article{142fbdbdea0e40809eb2a993c813a2b9,
title = "Treatment of lung large cell neuroendocrine carcinoma",
abstract = "Lung large cell neuroendocrine carcinoma (L-LCNEC) is a rare, aggressive, and difficult-to-treat tumor. It is classified as a neuroendocrine subtype of large cell lung carcinoma (LCLC) belonging to the non-small cell lung cancer (NSCLC) group, but it is also included in the neuroendocrine tumor (NET) group. Most of the available data related to its treatment derive from retrospective analyses or small case series. For patients with L-LCNEC, prognosis is generally very poor. In early stages (I–II–III), surgery is recommended but does not seem to be sufficient. Platinum-based adjuvant chemotherapy may be useful while the role of neoadjuvant chemotherapy is still not well defined. In patients with advanced L-LCNEC, the chemotherapy regimens used in SCLC still remain the standard of treatment, but results are not satisfactory. Due to their peculiar clinical and biological features and the lack of literature data, there is an emerging need for a consensus on the best treatment strategy for L-LCNEC and for the identification of new therapeutic options. In this review, we will discuss the key aspects of L-LCNEC management with the aim to clarify the most controversial issues.",
keywords = "Chemotherapy, Large cell neuroendocrine carcinoma, Lung neuroendocrine tumor, Treatment options",
author = "{Lo Russo}, Giuseppe and Sara Pusceddu and Claudia Proto and Marianna Macerelli and Diego Signorelli and Milena Vitali and Monica Ganzinelli and Rosaria Gallucci and Nicoletta Zilembo and Marco Platania and Roberto Buzzoni and {de Braud}, Filippo and Garassino, {Marina Chiara}",
year = "2016",
month = "3",
day = "4",
doi = "10.1007/s13277-016-5003-4",
language = "English",
pages = "1--11",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Treatment of lung large cell neuroendocrine carcinoma

AU - Lo Russo, Giuseppe

AU - Pusceddu, Sara

AU - Proto, Claudia

AU - Macerelli, Marianna

AU - Signorelli, Diego

AU - Vitali, Milena

AU - Ganzinelli, Monica

AU - Gallucci, Rosaria

AU - Zilembo, Nicoletta

AU - Platania, Marco

AU - Buzzoni, Roberto

AU - de Braud, Filippo

AU - Garassino, Marina Chiara

PY - 2016/3/4

Y1 - 2016/3/4

N2 - Lung large cell neuroendocrine carcinoma (L-LCNEC) is a rare, aggressive, and difficult-to-treat tumor. It is classified as a neuroendocrine subtype of large cell lung carcinoma (LCLC) belonging to the non-small cell lung cancer (NSCLC) group, but it is also included in the neuroendocrine tumor (NET) group. Most of the available data related to its treatment derive from retrospective analyses or small case series. For patients with L-LCNEC, prognosis is generally very poor. In early stages (I–II–III), surgery is recommended but does not seem to be sufficient. Platinum-based adjuvant chemotherapy may be useful while the role of neoadjuvant chemotherapy is still not well defined. In patients with advanced L-LCNEC, the chemotherapy regimens used in SCLC still remain the standard of treatment, but results are not satisfactory. Due to their peculiar clinical and biological features and the lack of literature data, there is an emerging need for a consensus on the best treatment strategy for L-LCNEC and for the identification of new therapeutic options. In this review, we will discuss the key aspects of L-LCNEC management with the aim to clarify the most controversial issues.

AB - Lung large cell neuroendocrine carcinoma (L-LCNEC) is a rare, aggressive, and difficult-to-treat tumor. It is classified as a neuroendocrine subtype of large cell lung carcinoma (LCLC) belonging to the non-small cell lung cancer (NSCLC) group, but it is also included in the neuroendocrine tumor (NET) group. Most of the available data related to its treatment derive from retrospective analyses or small case series. For patients with L-LCNEC, prognosis is generally very poor. In early stages (I–II–III), surgery is recommended but does not seem to be sufficient. Platinum-based adjuvant chemotherapy may be useful while the role of neoadjuvant chemotherapy is still not well defined. In patients with advanced L-LCNEC, the chemotherapy regimens used in SCLC still remain the standard of treatment, but results are not satisfactory. Due to their peculiar clinical and biological features and the lack of literature data, there is an emerging need for a consensus on the best treatment strategy for L-LCNEC and for the identification of new therapeutic options. In this review, we will discuss the key aspects of L-LCNEC management with the aim to clarify the most controversial issues.

KW - Chemotherapy

KW - Large cell neuroendocrine carcinoma

KW - Lung neuroendocrine tumor

KW - Treatment options

UR - http://www.scopus.com/inward/record.url?scp=84960106252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960106252&partnerID=8YFLogxK

U2 - 10.1007/s13277-016-5003-4

DO - 10.1007/s13277-016-5003-4

M3 - Article

AN - SCOPUS:84960106252

SP - 1

EP - 11

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

ER -